
What is claimed is:

1. A compound of formula (Ia):



(Ia)

wherein

R^1 is C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, 4-6 membered heterocycloalkyl, or 4-6 membered heteroaryl, wherein the C_1-C_6 alkyl is optionally substituted by one, two or three substituents selected from the group consisting of halogen, hydroxy, and C_1-C_3 alkoxy, further wherein the C_3-C_6 cycloalkyl, the 4-6 membered heterocycloalkyl, and the 4-6 membered heteroaryl are each independently optionally substituted by one, two or three substituents selected from the group consisting of C_1-C_3 alkyl, hydroxy, and C_1-C_3 alkoxy;

ring A is C_6-C_{10} aryl or 5-12 membered heteroaryl;

R^2 and R^5 are each independently absent, hydrogen, halogen, cyano, difluoromethyl, trifluoromethyl, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 alkoxy, -$N(R^{10})(R^{11})$, C_3-C_5 cycloalkyl, or 4-6 membered heterocycloalkyl, wherein the C_1-C_6 alkyl is optionally substituted by one, two or three substituents selected from the group consisting of halogen, hydroxy, C_1-C_6 alkoxy, and -$N(R^{12})(R^{13})$;


R^3 is absent, hydrogen, halogen, C_1-C_6 alkyl, C_2-C_6 alkynyl, C_1-C_6 alkoxy, C_3-C_7 cycloalkyl, or 3-7 membered heterocycloalkyl, wherein the C_1-C_6 alkyl and the C_1-C_6 alkoxy are each optionally substituted by one, two or three R^{14} groups, and further wherein the C_3-C_7 cycloalkyl and the 3-7 membered heterocycloalkyl are each optionally substituted by one, two or three R^{15} groups;

R^4 is absent, hydrogen, halogen, C_1-C_6 alkyl, or C_3-C_6 cycloalkyl,


wherein R^2 and R^3 or R^3 and R^4 may combine to form a C_5-C_7 cycloalkyl ring or a 5-7 membered heterocycloalkyl ring, further wherein the C_5-C_7 cycloalkyl ring and the 5-7 membered heterocycloalkyl ring are each independently optionally substituted by one, two or three R^{14} groups;

R^6 and R^8 are each independently absent, hydrogen, halogen, cyano, hydroxy, difluoromethyl, trifluoromethyl, C_1-C_3 alkyl, C_1-C_3 alkoxy, or C_3-C_5 cycloalkyl, wherein the C_1-C_3 alkyl is optionally substituted by hydroxy, difluoromethyl, trifluoromethyl, C_1-C_3 alkoxy, or C_3-C_5 cycloalkyl;

R^7 is



or



;

G is $-NR^{18}$;

R^{12} and R^{13} are each independently hydrogen or C_1-C_3 alkyl;

R^{10} and R^{11} are each independently hydrogen or C_1-C_6 alkyl; or R^{10} and R^{11} together with the nitrogen to which they are attached, may combine to form a 4-7 membered heterocycloalkyl ring, when R^{10} and R^{11} are each C_1-C_3 alkyl, wherein the 4-7 membered heterocycloalkyl ring formed is optionally substituted by one, two, three or four R^{15} groups;

each R^{14} is independently halogen, cyano, C_1-C_3 alkyl, hydroxy, C_1-C_6 alkoxy, $-N(R^{19})(R^{20})$, $-CON(R^{21})(R^{22})$, or 3-7 membered heterocycloalkyl, wherein the 3-7 membered heterocycloalkyl is optionally substituted by one, two, three or four R^{15} groups;

each R^{15} is independently halogen, C_1-C_3 alkyl, hydroxy, C_1-C_6 alkoxy, $-NH_2$, $-NHCH_3$, or $-N(CH_3)_2$;

R^{16} and R^{17} are each independently hydrogen or C_1-C_6 alkyl, wherein the C_1-C_6 alkyl is optionally substituted by $-N(R^{23})(R^{24})$,

provided that R^{16} and R^{17} may form a C_3-C_5 cycloalkyl ring;

R^{18} is hydrogen or C_1-C_3 alkyl;

each R^{19}, R^{20}, R^{21}, R^{22}, R^{23}, and R^{24} is independently hydrogen or C_1-C_3 alkyl;

n is 0, 1, or 2; and

p is 0, 1, or 2; or

a pharmaceutically acceptable salt thereof.

2. The compound or salt of claim 1, wherein R^1 is C_1-C_6 alkyl or C_3-C_6 cycloalkyl, wherein the C_1-C_6 alkyl is optionally substituted by hydroxy, and further wherein the C_3-C_6 cycloalkyl is optionally substituted by C_1-C_3 alkyl.

3. The compound or salt of claim 1, wherein R^1 is methyl, ethyl, isopropyl, or tert-butyl.

4. The compound or salt of any one of claims 1-3, wherein R^2 is hydrogen, methyl, difluoromethyl, or methoxy.


5. The compound or salt of any one of claims 1-3, wherein R^5 is hydrogen, C_1-C_6 alkyl, or C_1-C_6 alkoxy.

6. The compound or salt of any one of claims 1-3, wherein R^5 is hydrogen, methyl, or methoxy.

7. The compound or salt of any one of claims 1-3, wherein R^3 is C_1-C_6 alkyl or 3-7 membered heterocycloalkyl, wherein the C_1-C_6 alkyl is optionally substituted by one or two R^{14} groups, and further wherein the 3-7 membered heterocycloalkyl is optionally substituted by C_1-C_3 alkyl.

8. The compound or salt of any one of claims 1-3, wherein R^3 is methyl.

9. The compound of any one of claims 1-3, having formula (IIa):



(IIa)

or a pharmaceutically acceptable salt thereof,

wherein

X is CH or N;


W is CR^2 or N,

provided that one of X and W is N and X and W cannot both be N, and further provided that when W is CR^2, at least one of R^2 and R^5 is hydrogen;

R^2 and R^5 are each independently hydrogen, halogen, cyano, difluoromethyl, trifluoromethyl, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 alkoxy, -N(R^{10})(R^{11}), C_3-C_5 cycloalkyl, or 4-6 membered heterocycloalkyl, wherein the C_1-C_6 alkyl is optionally substituted by one, two or three substituents selected from the group consisting of halogen, hydroxy, C_1-C_6 alkoxy, and -N(R^{12})(R^{13}); and

R^3 is hydrogen, halogen, C_1-C_6 alkyl, C_2-C_6 alkynyl, C_1-C_6 alkoxy, C_3-C_7 cycloalkyl, or 3-7 membered heterocycloalkyl, wherein the C_1-C_6 alkyl and the C_1-C_6 alkoxy are each optionally substituted by one, two or three R^{14} groups, and further wherein the C_3-C_7 cycloalkyl and the 3-7 membered heterocycloalkyl are each optionally substituted by one, two or three R^{15} groups.

10. The compound of any one of claims 1-3, having formula (IIIa):



(IIIa)

or a pharmaceutically acceptable salt thereof,

wherein

R^2 and R^5 are each independently hydrogen, halogen, cyano, difluoromethyl, trifluoromethyl, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 alkoxy, -N(R^{10})(R^{11}), C_3-C_5 cycloalkyl, or 4-6 membered heterocycloalkyl, wherein the C_1-C_6 alkyl is optionally

substituted by one, two or three substituents selected from the group consisting of halogen, hydroxy, C_1-C_6 alkoxy, and -N(R^{12})(R^{13}),

provided that at least one of R^2 and R^5 is hydrogen; and

R^3 is hydrogen, halogen, C_1-C_6 alkyl, C_2-C_6 alkynyl, C_1-C_6 alkoxy, C_3-C_7 cycloalkyl, or 3-7 membered heterocycloalkyl, wherein the C_1-C_6 alkyl and the C_1-C_6 alkoxy are each optionally substituted by one, two or three R^{14} groups, and further wherein the C_3-C_7 cycloalkyl and the 3-7 membered heterocycloalkyl are each optionally substituted by one, two or three R^{15} groups.

11. The compound or salt of claim 1, 9 or 10, wherein n is 0.

12. The compound or salt of claim 1, 9, or 10, wherein n is 1.

13. The compound or salt of claim 1, 9, or 10, wherein p is 1.

14. The compound or salt of claim 1, 9, or 10, wherein n is 1 and p is 1.


15. The compound or salt of claim 1, 9, or 10, wherein R^6 and R^8 are each independently hydrogen, halogen, C_1-C_3 alkyl, or C_1-C_3 alkoxy.

16. The compound or salt of claim 1, 9, or 10, wherein R^6 is hydrogen, fluorine, methyl, or methoxy.

17. The compound or salt of claim 1, 9, or 10, wherein R^6 is fluorine.

18. The compound or salt of claim 1, 9, or 10, wherein R^8 is hydrogen, fluorine, or methyl.

19. The compound of claim 1, 9, or 10, having formula (IIIb):




(IIIb)

,

or a pharmaceutically acceptable salt thereof.

20. A compound, which is




,

or a pharmaceutically acceptable salt thereof.

21. A pharmaceutical composition comprising a compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.

22. A pharmaceutical composition comprising a compound, which is



,

or a pharmaceutically acceptable salt thereof , and a pharmaceutically acceptable carrier or diluent.

23. A compound of any one of claims 1-20, or a pharmaceutically acceptable salt thereof, that is effective in treating abnormal cell growth, for use in the treatment of abnormal cell growth in a mammal.